Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Gemcitabine and Cisplatin in NPC
NCT01417390Phase 2Unknown
- Sponsor
- Foshan First People's Hospital
- Start
- Nov 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoints: Failure-free survival at 3 years, Response rates after radiotherapy and 2 more. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01417390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417390.